• PDF / 169,117 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 71 Downloads / 159 Views

DOWNLOAD

REPORT

---

1 S

Thrombocytopenia: case report In a retrospective, non-randomised, single-institutional study of 24 patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer (ABC) received treatment between October 2017 to January 2019 in India, one woman [age not stated] was described, who developed thrombocytopenia during treatment with letrozole and palbociclib for HR-positive, HER2-negative ABC. The previously untreated, postmenopausal woman received scheduled treatment with letrozole 2.5 mg/day tablet and palbociclib 125mg capsule, 3 out of 4 weeks in a 28 day for her HR-positive, HER2-negative ABC. She developed side-effect of thrombocytopenia, but the treatment was continued [duration of treatment to reaction onset and outcome not stated]. Gnanaguru V, et al. Letrozole and palbociclib in advanced breast cancer: Outcome from cancer institute, Chennai. Indian Journal of Medical and Paediatric Oncology 41: 803497731 182-186, No. 2, Apr 2020. Available from: URL: http://doi.org/10.4103/ijmpo.ijmpo_156_19

0114-9954/20/1818-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 22 Aug 2020 No. 1818